Stay updated on Pembrolizumab SubQ vs IV in Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference6%
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.3%
- Check46 days agoChange DetectedThe web page has been updated to version 2.15.0 from version 2.14.4, indicating a revision in the content. The phrase 'Here’s how you know' has been modified, suggesting a change in the way information is presented.SummaryDifference1.0%
- Check53 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 10, 2025, while a date for March 25, 2025, has been removed.SummaryDifference1.0%
- Check96 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check103 days agoChange DetectedThe date for results has been updated from December 18, 2023, to February 10, 2025, indicating a significant delay in the timeline for results posting.SummaryDifference1%
Stay in the know with updates to Pembrolizumab SubQ vs IV in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab SubQ vs IV in Melanoma Clinical Trial page.